SOLENO THERAPEUTICS INC
Rank #219HypergrowthSLNO
SOLENO THERAPEUTICS INC (SLNO) — Rank #219 by gross profitability (GP/assets 0.31) · ROE 4.2% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001484565 · all metrics point-in-time as of the filing date.
About
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
Disclosure regression check
4 previously-disclosed line items are no longer reported. Worth checking the filing for why.
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.31
Primary signal (Novy-Marx).
5th of 9 SIC 2834 peers
Return on equity
4.2%
Gross margin
98.6%
1st of 9 SIC 2834 peers
Revenue growth (YoY)
31243.8%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2013 | 2014 | 2015 | 2016 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.23
1st of 9 SIC 2834 peers (best = lowest)
Current ratio
5.62×
1st of 9 SIC 2834 peers
Quick ratio
5.22×
Net cash
$479.11M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$46.73M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
1.24
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
24.1%
Stock-based comp intensity.
Piotroski F-Score
F-Score
N/A
Only 8/9 components determinable.